Macitentan/Tadalafil

马昔腾坦/他达拉非

Report date: 2026/01/30 17:24:17

Base Information

Drug NameMacitentan/Tadalafil
Drug Alias Name他达拉非+马西替坦Tadalafil/MacitentanMacitentan+Tadalafil马西替坦+他达拉非Tadalafil+Macitentan +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 5A inhibitorsEndothelin receptor type A antagonistsEndothelin receptor type B antagonists
TargetsPhosphodiesterase 5AEndothelin receptor type AEndothelin receptor type B
Therapy Area/IndicationsPhenylketonuriasPulmonary Arterial Hypertension
Global Approved IndicationsPulmonary Arterial Hypertension
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2024/03/22
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsYes MacitentanTadalafil
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesActelion Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesActelion Pharmaceuticals Us IncJohnson & Johnson (China) Investment LtdJanssen-Cilag International Nv +[7] 
Inactive CompaniesJanssen Pharmaceutical Ltd
Active IndicationsPhenylketonuriasPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A